Cidofovir in the treatment of poxvirus infections (Q34134474)

31 July 2017

1 reference

title

Cidofovir in the treatment of poxvirus infections (English)

1 reference

Poxviridae infectious disease

31 July 2017

main subject

1 reference

Erik De Clercq

0 references

1 July 2002

1 reference

31 July 2017

1 reference

31 July 2017

1 reference

31 July 2017

1 reference

31 July 2017

page(s)

1-13

1 reference

Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells.

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Uveitis in patients treated with intravenous cidofovir

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Vero cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Topical cidofovir for severe molluscum contagiosum

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

In search of a selective antiviral chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

A novel selective broad-spectrum anti-DNA virus agent

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

A case of human orf in an immunocompromised patient treated successfully with cidofovir cream

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Efficacy of cidofovir in the treatment of recalcitrant molluscum contagiosum in an AIDS patient

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Progressive Vaccinia Treated with Ribavirin and Vaccinia Immune Globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

A Randomized, Double‐Blind, Placebo‐Controlled Trial of Cidofovir Gel for the Treatment of Acyclovir‐Unresponsive Mucocutaneous Herpes Simplex Virus Infection in Patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Resolution of Recalcitrant Molluscum Contagiosum Virus Lesions in Human Immunodeficiency Virus-Infected Patients Treated With Cidofovir

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Parapoxviruses are strongly inhibited in vitro by cidofovir

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Efficacy of 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purine for treatment of vaccinia virus (orthopoxvirus) infections in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG).

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Clinical uses of cidofovir

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis: the HPMPC Peripheral Cytomegalovirus Retinitis Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Topical cidofovir: a novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

Topical and intralesional cidofovir: a review of pharmacology and therapeutic effects.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900008-6

7 January 2021

10.1016/S0166-3542(02)00008-6

Identifiers

DOI

1 reference

31 July 2017

1 reference